Avery Fairbank

From startup to IPO, from lab to FDA approval.... Exclusively representing an MD/PhD Chief Medical Officer looking for Board Opportunities! ✅ Multiple FDA approvals (ADC for breast cancer, CAR-T therapy) ✅ Scaled biotech from 17-person private to 150+person public company ✅ 6+ years Public BoD experience - immuno-oncology biotech Seeking biotech boards that value deep scientific expertise and proven leadership. Interested? DM for details. #Biotech #BoardOfDirectors #Oncology

Billion-Dollar Bottleneck: The GLP-1 Manufacturing Dilemma While GLP-1 therapies are reshaping obesity treatment, a critical challenge looms: manufacturing capacity. Despite soaring revenues, Eli Lilly and Novo Nordisk are grappling with unprecedented challenges in ramping up production to meet the surging global demand. Key developments in addressing the manufacturing bottleneck: Novo Nordisk's strategic move: $14B acquisition of CDMO Catalent Pharma Solutions Eli Lilly and Company's expansion: Breaking ground on a new $2.5B site in Germany & an additional $800M invested at one of its Ireland sites. The ripple effect: CDMOs investing heavily to capture GLP-1 manufacturing opportunities: Corden Pharma - A Full-Service CDMO: $900M in expansions across US/Europe Simtra BioPharma Solutions: $250M Sterile Fill/Finish expansion (Indiana) Resilience: $225M Fill/Finish expansion (Ohio) Agilent Technologies: $925M acquisition of BIOVECTRA Argonaut Manufacturing Services Inc.: $45M Sterile Fill/Finish expansion (California) Vetter Pharma: $252M, 57,000 sqft Aseptic site (Germany) PCI Pharma Services: $100M Sterile Fill/Finish expansion (Philadelphia) As the industry races to scale up GLP-1 production, its capacity to meet demand will be pivotal in realizing the full potential of this game-changing treatment approach. #GLP1Manufacturing #CDMO #ObesityTreatment

The Rise of GLP-1 Therapies in Obesity Treatment The pharmaceutical landscape is witnessing a seismic shift with the emergence of GLP-1 therapies for obesity. First-mover companies, Eli Lilly and Novo Nordisk have skyrocketed to become the most valuable pharmaceuticals, driven by the success of their GLP-1 drugs. As the obesity market potentially reaches $100B by 2030 (Goldman Sachs Research), competition is intensifying. Aside from pharmaceuticals, here are some biotechs to keep an eye out for: Altimmune, Inc.: Pemvidutide (Phase II) Innovent Biologics: Mazdutide (Phase III) Viking Therapeutics, Inc.: VK2735 (Phase II) BioAge Labs: Azelaprag (Phase II) Carmot Therapeutics, Inc.: CT-868 (Phase II) Zealand Pharma: Dapiglutide (Phase II) Structure Therapeutics: GSBR-1290 (Phase III) Rivus Pharmaceuticals : HU6 (Phase II) Kallyope: K-757/K-833 (Phase II) Aardvark Therapeutics ARD-101 (Phase II) These companies are exploring diverse approaches, from peptide-based agonists to oral small molecules, targeting various receptors and pathways. The race is on to capture market share and potentially revolutionize obesity treatment. #ObesityTreatment #GLP1Therapies #BiotechInnovation

Happy Labor Day! Raising a toast to hard work and well-deserved rest.

Exciting times ahead! I’m delighted to announce the official launch of VAAAS - a Specialist Virtual Recruitment Assistant solution. VAAAS offers specially trained Virtual Recruitment Assistants that reclaim lost hours, boost efficiency, and reduce operational costs while increasing profitability, all while helping your recruitment business scale and improve work-life balance. Whether it's managing tedious tasks so top performers can excel, or providing strategic support to assist with business development efforts, VAAAS is here to optimise your recruitment firm. Interested in learning more visit www.vaaas.com for details.

Today, as a culmination of our #AdvancedTechnology series, we delve into the transformative world of Nanotechnology. This sector is not just growing; it's revolutionising industries from medicine to electronics, pushing the boundaries of what's possible. Europe emerges as a powerhouse in nanotech, following Asia's lead. With a global industry worth £111.25 billion, the biomedical, electronics, and energy sectors dominate, presenting abundant career opportunities. The US is at the forefront of the nanotech job market, boasting average salaries of $99,040 for Nanotechnology Engineers. As the demand for computer chips and medical devices surges, niche roles such as Nanomaterial Scientists and Nanorobotics Engineers become increasingly pivotal. Looking forward, the trajectory for nanotech is set to soar, with projections hitting £288.71 billion by 2030, complemented by a robust 10.6% growth in the US job market. Dive deeper into these insights and more with the full 2023 Advanced Technology Market Analysis Report. Find the link to download in the comments below. #Nanotechnology #Nanorobotics #Nanoscience

Today, let's explore the rise of data centres in the #AdvancedTech industry. 2023 saw an unprecedented surge in data centre facilities, driven by a 70% spike in internet usage and a 12% increase in streaming during the 2020 lockdowns. Coupled with 5G adoption and AI's influence on semiconductors, Q2 2023 witnessed a remarkable 15% quarter-over-quarter growth in data processing. While Europe navigates the hurdles of skilled labour shortages, the Asia-Pacific region is flourishing, with significant investments transforming Singapore and Hong Kong into leading tech hubs. Looking ahead, sustainability emerges as a pivotal focus. An impressive 87% of executives are committed to amplifying investments in energy efficiency and renewable resources, heralding a new era of eco-conscious data centres. Stay tuned as we cover the last trend in our report. Details to download the full 2023 Advanced Technology Market Analysis report can be found in the comments below. #TechTrends #DataCentre #Sustainability

This week marks the culmination of our insightful market analysis series, as we explore the transformative trends shaping the industry in the past year. The AI revolution is in full swing, highlighting its profound influence across global business landscapes. Moving beyond its early 'nerd-tech' perception, AI now stands as a pivotal element within 35% of companies, demonstrating its indispensable role in driving innovation and efficiency. Our analysis unveils a thriving job market, spotlighting the surge in demand for Machine Learning Engineers and Data Scientists. Looking ahead, we're optimistic about AI’s capacity to generate 12 million new jobs worldwide by 2025, illuminating a future brimming with opportunities. For an in-depth exploration of these groundbreaking insights and to discover how AI can propel your business forward, you may download the full report through the link in the comment section. #AI #Technology #BusinessGrowth #GlobalJobMarket

Today, let's delve into the future of the Neurotechnology sector. By 2030, this sector is predicted to soar, fuelled by increased research funding, rising prevalence of neurological disorders, and global government support. Cutting-edge trends like neuroinformatics, neuroplasticity interventions, and brain mapping initiatives are reshaping the market, alongside non-invasive brain stimulation techniques and remote monitoring solutions. Conditions such as Alzheimer's disease and epilepsy are driving forces behind this growth, while boosted healthcare expenditure globally signals a promising future for Neurotechnology. Stay tuned next week as we explore overarching trends in the #AdvancedTech industry. Find details to download the full Advanced Technology Market Analysis Report in the comment section below. #Neurotechnology #Neuroinformatics #Healthcare